

Confirmed Speakers

Plenary Speakers

First Time Disclosure

The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders (IL09)



Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Derivatives of 1,3,5-triazine as a New Trend in the Search for the 5-HT₆ Receptor Ligands with Therapeutic Perspectives (PL01)



Prof. Jadwiga HANDZLIK
(MEDICAL COLLEGE OF JAGIELLONIAN UNIVERSITY, Krakow, Poland)

Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders (PL02)



Prof. Krzysztof PALCZEWSKI
(CASE WESTERN RESERVE UNIVERSITY, Cleveland, United States)

Next Generation Pain Therapeutics for the Opioid Crisis: Design of Bifunctional Nociceptin/Mu Opioid GPCR Ligands as non-Addicting Analgesics (PL03)



Dr Nurulain ZAVERI
(ASTRAEA THERAPEUTICS, Mountain View, United States)

Matrix Metallo-Proteinases

Libraries of Fluorogenic Substrates with Natural and Unnatural Amino Acids as a Tool in Design of Active and Specific Probes for Investigation of Proteolytic Enzymes (IL01)



Prof. Marcin DRAG
(WROCLAV UNIVERSITY OF TECHNOLOGY, Wroclaw, Poland)

MMP-9 at the Synapse in the Brain and Mind (IL02)



Prof. Leszek KACZMAREK
(NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY, Warsaw, Poland)

Metalloproteinase Cleavage Control of Interferon Alpha and Gamma Dampens Inflammation and Anti-Viral Immunity (IL03)



Prof. Christopher OVERALL
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

Chemical Biology Tools & Target Engagement Technologies

Confirmed Speakers

Protein-Ligand Interactions: How Medicinal Chemistry Contributes to the Understanding of Molecular Recognition (IL17)



Dr Marc NAZARE
(FMP, Berlin, Germany)

Adventures in Targeting Protein Lipdation: Breaking Drug Resistance Using Fragment Deconstruction and Chemical Biology (IL18)



Prof. Edward TATE
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

Tankyrase Inhibitors : Evidence for Therapeutic Potential in Immuno-Oncology



Dr Luc VAN HIJFTE
(MERCACHEMSYNCOM, Nijmegen, The Netherlands)

GPCRs: a Discovery Powerhouse

Design of Orexin 1 Receptor Selective Antagonists (IL11)



Dr Uta LESSEL
(BOEHRINGER INGELHEIM PHARMA GMBH & CO KG, Biberach an der Riss, Germany)

Next Generation GPR119 Agonists as Potential Treatment for Cardiometabolic Diseases (IL12)



Dr Lothar SCHWINK
(SANOFI, Frankfurt Am Main, Germany)

G Protein-Coupled Receptors: the Structural Basis for their Pharmacology (IL10)



Dr Chris TATE
(MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom)

Genomics in Drug Discovery : Roles for Chemistry

Designing Synthetic Gene Regulators (SynGR) (IL04)



Prof. Aseem ANSARI
(UNIVERSITY OF WISCONSIN-MADISON, Madison, United States)

Exploring Bacterial Genomes for Natural Product Discovery and Development (IL05)



Prof. Alessandra S. EUSTAQUIO
(UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, United States)

Integrative Screening Identifies a Novel Node in the Oncogenic YAP/HIPPO Pathway (IL06)

Confirmed Speakers



Dr Mathias FREDERIKSEN
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (NIBR), Basel, Switzerland)

Specific and Multi-Targeted Drugs

Charting New Paths in Multi-Target Drug Discovery for Alzheimer's Disease (IL13)



Prof. Maria Laura BOLOGNESI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

Chemical Biology for Drug Discovery: A Click and Play Approach Exemplified by ERK1/2 Probes (OC03)



Dr Charlotte GRIFFITHS-JONES
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

Identification and in-vivo Efficacy Studies of a Nicotinamide Derivative as Novel NNMT Inhibitor (OC04)



Dr Sven RUF
(SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt am Main, Germany)

Multiple Targeting - The Histamine H3 Receptor Pharmacophore as Central Element (IL14)



Prof. Holger STARK
(HEINRICH HEINE UNIVERSITY DÜSSELDORF, Duesseldorf, Germany)

Targeted Covalent Inhibitors

Mining the Protein Kinase Cysteine (IL22)



Dr Tjeerd BARF
(ACERTA PHARMA BV, Oss, The Netherlands)

Safety First: Covalent Inhibitors from a Safety Perspective (IL20)



Dr Mickael MOGEMARK
(ASTRAZENECA, Mölndal, Sweden)

Adventures in Functional Assignment and Inhibition of Metallo-Enzymes (IL21)



Prof. Christopher J. SCHOFIELD
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Adding AI to the Drug Discovery Tool Box

Capturing and Applying Knowledge to Guide Compound Optimisation (OC10)

Confirmed Speakers



Dr Nick FOSTER
(OPTIBRIUM, Litlington, United Kingdom)

Learning the Art of Chemical Synthesis with Deep Neural Networks and Discipline Scale Data (IL23)



Prof. Mark WALLER
(UNIVERSITY OF WOLLONGONG, Wollongong, Australia)

Applications of Artificial Intelligence in Drug Discovery – Separating Hype From Utility (IL24)



Dr Patrick WALTERS
(RELAY THERAPEUTICS, Cambridge, MA, United States)

Augmented Intelligence for Compound Design (OC09)



Dr Michal WARCHOL
(ARDIGEN, Krakow, Poland)

Advances in Protein Degradation Technologies

Targeted Protein Degradation with Small Molecules: how PROTACs Work (IL07)



Prof. Alessio CIULLI
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Drugging Challenging E3 Ligases: A Novel Multidisciplinary Approach to Identify Small-Molecules that Bind FBW7 (OC02)



Ms Miriam MARTINEZ CARTRO
(UNIVERSITY OF BARCELONA, Barcelona, Spain)

The Ubiquitin System (IL08)



Prof. Huib OVAA
(LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, The Netherlands)

Small-Molecule Modulation of Cereblon Protein Level (OC01)



Dr Christian STEINEBACH
(UNIVERSITY OF BONN, Bonn, Germany)

Opioid, Pain, Endo-Cannabinoid

The Discovery and Development of the Clinical FAAH Inhibitor JNJ-42165279 (OC06)

Confirmed Speakers



Prof. James BREITENBUCHER
(UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States)

Potential of Natural Cannabinoids and Synthetic Cannabinoids in Neuroprotection (IL16)



Prof. Rafael FRANCO
(UNIVERSITY OF BARCELONA, Barcelona, Spain)

Cannabinoid Receptor Type 2 Modulation to Improve Outcomes for Cartilage Repair in the Osteoarthritic Joint (IL15)



Prof. Katarzyna STAROWICZ-BUBAK
(INSTITUTE OF PHARMACOLOGY, POLISH ACADEMY OF SCIENCES, Krakow, Poland)

Discovery of Best in-class, Novel, Selective, Potent and Peripheral FLT3 Inhibitors, a New Way to Treat Neuropathic Pain (OC05)



Dr Dominique SURLERAUX
(BCI PHARMA, Liège, Belgium)

Pharma Research Highlights in Poland

Discovery of OAT-2068 - A Potent, Selective, Orally Bioavailable Inhibitor of Mouse Chitotriosidase and its In Vivo Activity in the Bleomycin-Induced Pulmonary Fibrosis Model in Mice (OC07)



Dr Agnieszka BARTOSZEWICZ
(MOLECURE S.A, Warszawa, Poland)

DPD-inspired Small Heterocyclic Libraries Characterized as Novel LsrK Kinase Inhibitors: an Opportunity to Fight Antimicrobial Resistance (OC08)



Dr Anna KARAWAJCZYK
(SELVITA, Krakow, Poland)